IRVINE, Calif., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today it will present at the 36th Annual Canaccord Genuity Growth Conference in Boston, MA.
| Event: | 36th Annual Canaccord Genuity Growth Conference |
| Date: | Wednesday, August 10, 2016 |
| Time: | 5:00 pm ET / 2:00 pm PT |
| Participant: | John McDermott, Chief Executive Officer |
An audio webcast of the Company’s presentation at the conference will be available by visiting the investor relations section of Endologix’s website at www.endologix.com. A replay of the presentation will be available for 30 days.
About Endologix, Inc.
Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's website at www.endologix.com.